主页 > 医药科学 >
¡¾medical-news¡¿ÆľßÏ£ÍûµÄ¶ù¿Æ¿¹°©Ò©»
WASHINGTON (Reuters) - A compound that looked promising for treating a brain tumor found mostly in children may damage growing bone -- possibly making it too dangerous to use in young patients, researchers reported on Monday.
The drug fully eradicated medulloblastoma tumors in mice in 2004. But further testing showed it caused permanent bone damage in immature mice, Tom Curran of The Children's Hospital of Philadelphia and colleagues found.
Writing in the journal Cancer Cell, they said the drug, known by its experimental name HhAntag, will need to be developed with caution.
And, they said, similar drugs will need careful testing.
HhAntag, made by California-based Genentech, affects a gene called Hedgehog, involved in both normal development and in cancer.
It is a so-called signal transduction inhibitor, designed to interrupt Hedgehog's cancer-causing effects.
Several such drugs are currently in pediatric clinical trials.
"While it is not clear that the bone defects we observed in mice would also occur in children, and while signal transduction inhibitors may still represent a highly promising approach to treating pediatric cancer, it may be important to perform preclinical testing in young animals before moving ahead to clinical trials," Curran said in a statement.
Medulloblastomas account for about one in five childhood brain tumors.
http://www.reuters.com/article/healthNews/idUSN1050114020080310 Promising cancer drug may endanger child's bones
ÆľßÏ£ÍûµÄ¶ù¿Æ¿¹°©Ò©»áË𺦹Ç÷À
WASHINGTON (Reuters) - A compound that looked promising for treating a brain tumor found mostly in children may damage growing bone -- possibly making it too dangerous to use in young patients, researchers reported on Monday.
»ªÊ¢¶Ù£¨Â·Í¸É磩-ÖÜÒ»Ñо¿ÈËÔ±±¨µÀ£¬Ò»ÖÖ¿´ËƺÜÓÐÇ°¾°µÄÖÎÁƶùͯÄÔÖ×ÁöµÄÒ©Îï¿ÉÄÜ»áË𺦹Ç÷À·¢Óý¡ª¡ª¼«ÓпÉÄÜÒòΪÆäΣÏÕÐÔ¶øÎÞ·¨ÓÃÓÚ¶ùͯ¡£
The drug fully eradicated medulloblastoma tumors in mice in 2004. But further testing showed it caused permanent bone damage in immature mice, Tom Curran of The Children's Hospital of Philadelphia and colleagues found.
¸ÃÒ©ÓÚ2004Äê±»·¢ÏÖ¿ÉÒÔÖÎÁÆСÊó³ÉÉñ¾¹Üϸ°ûÁö£¬ºóÀ´·Ñ³Ç¶ùͯҽԺµÄTom Curran½øÒ»²½Ñо¿·¢ÏÖ£¬Ëü»áÒýÆðδ³ÉÄêÊóµÄÓÀ¾ÃÐÔ¹Ç÷ÀË𺦡£
Writing in the journal Cancer Cell, they said the drug, known by its experimental name HhAntag, will need to be developed with caution.
×÷ÕßÔÚCancer CellÔÓÖ¾ÉÏдµÀ£¬±»ÊµÑéÐÔ³ÆΪ HhAntagµÄÒ©Îï±ØÐë½÷É÷¿ª·¢¡£
And, they said, similar drugs will need careful testing.
ËûÃÇ»¹Ëµ£¬ÀàËƵÄÒ©ÎïÐèҪСÐļì²â¡£
HhAntag, made by California-based Genentech, affects a gene called Hedgehog, involved in both normal development and in cancer.
HhAntagÓÉ×ܲ¿ÉèÔÚ¼ÓÀû¸£ÄáÑǵÄGenentech¹«Ë¾Éú²ú£¬¸ÃÒ©Ö÷Òª×÷ÓÃÓÚ Hedgehog »ùÒò£¬¶ø Hedgehog»ùÒòÓëÕý³£·¢ÓýºÍ°©Ö¢¾ùÓйء£
It is a so-called signal transduction inhibitor, designed to interrupt Hedgehog's cancer-causing effects.
¸ÃÒ©ÊÇÒ»ÖÖÐźÅתµ¼ÒÖÖƼÁ£¬ÓÃÓÚ×è¶Ï Hedgehog»ùÒòµÄÖ°©Ð§Ó¦¡£
Several such drugs are currently in pediatric clinical trials.
ÓëÖ®ÀàËƵļ¸¸öÒ©ÎïÄ¿Ç°¾ùÔÚ½øÐжù¿ÆÁÙ´²ÊÔÑé¡£
"While it is not clear that the bone defects we observed in mice would also occur in children, and while signal transduction inhibitors may still represent a highly promising approach to treating pediatric cancer, it may be important to perform preclinical testing in young animals before moving ahead to clinical trials," Curran said in a statement.
CurranÔÚÒ»ÏîÉùÃ÷Öгƣ¬¡°Ä¿Ç°»¹²»Çå³þÔÚСÊóÉíÉϹ۲쵽µÄ¹Ç÷ÀËðº¦ÊÇ·ñÒ²»á·¢ÉúÔÚ¶ùͯÉíÉÏ¡£ËäÈ»ÐźÅתµ¼ÒÖÖƼÁ¿ÉÄÜ´ú±íÁËÒ»ÖÖ¼«ÓÐÏ£ÍûÖÎÁƶù¿Æ°©Ö¢µÄ·½·¨£¬µ«ÔÚ½øÐÐÁÙ´²ÊÔÑé֮ǰ£¬¶ÔÓ×Ä궯Îï½øÐÐÁÙ´²Ç°ÊÔÑé·Ç³£ÖØÒª¡£¡±
Medulloblastomas account for about one in five childhood brain tumors.
ÔÚ¶ùͯÄÔÁö»¼ÕßÖУ¬³ÉÉñ¾¹Üϸ°ûÁöÔ¼Õ¼Îå·ÖÖ®Ò»¡£
±àÒ룺
ÆľßÏ£ÍûµÄ¶ù¿Æ¿¹°©Ò©»áË𺦹Ç÷À
»ªÊ¢¶Ù£¨Â·Í¸É磩£ºÖÜÒ»Ñо¿ÈËÔ±±¨µÀ£¬Ò»ÖÖ¿´ËƺÜÓÐÇ°¾°µÄÖÎÁƶùͯÄÔÖ×ÁöµÄÒ©Îï¿ÉÄÜ»áË𺦹Ç÷À·¢Óý¡ª¡ª¼«ÓпÉÄÜÒòΪÆäΣÏÕÐÔ¶øÎÞ·¨ÓÃÓÚ¶ùͯ¡£
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-10 05:14
医学,生命科学网